Wellness and Longevity Medicine
Can NAD Supplements Slow Aging? What Human Studies Actually Show
NMN and NR can increase NAD-related biomarkers, but that does not prove they reverse aging or extend life. Here is what human trials show, where the evidence remains uncertain, and what consumers should consider before buying an NAD supplement.

NAD supplements have moved rapidly from research laboratories into wellness clinics, capsules, powders, and intravenous infusions. Marketing often promises more energy, sharper thinking, faster recovery, or even “reversed” aging.
The biology behind the excitement is real. Nicotinamide adenine dinucleotide, usually shortened to NAD+, is essential for cellular energy metabolism and also participates in signaling, DNA repair, and stress-response pathways. The commercial claims, however, have advanced much faster than the clinical evidence.
Human studies show that some NAD precursors can raise NAD-related compounds in blood or selected tissues. They have not established that these products extend human life, prevent dementia, reverse biological aging, or reliably improve how a generally healthy person feels or functions.
NAD+, NMN, and NR Are Related, but Not Identical
NAD+ is a molecule already present in every cell. The body can make it through several pathways using nutritional building blocks, including forms of vitamin B3.
Most oral “NAD boosters” contain one of two precursors:
- Nicotinamide riboside (NR): A form of vitamin B3 that the body can use to produce NAD+.
- Nicotinamide mononucleotide (NMN): Another compound in the NAD+ production pathway.
A capsule containing NR, a capsule containing NMN, an oral product labeled NAD+, and an NAD+ infusion are not interchangeable. They differ in absorption, metabolism, dose, product quality, and route-related risks. A study of oral NR cannot validate an NMN powder or an intravenous NAD+ package simply because each product uses the same acronym in its advertising.
Raising a Biomarker Is Not the Same as Slowing Aging
Early trials have repeatedly shown that NAD precursors can change biochemical measurements. For example, a 2018 randomized crossover trial enrolled healthy adults ages 55 to 79. Twenty-four participants completed six weeks each of NR and placebo. NR increased NAD+ in peripheral blood mononuclear cells by about 60 percent and was generally well tolerated during the study.
That finding demonstrated biological activity. It did not demonstrate broad rejuvenation. The trial found no improvement in body composition, glucose regulation, maximal exercise capacity, or overall motor function. Possible changes in blood pressure and arterial stiffness were exploratory and did not remain statistically significant after adjustment for multiple comparisons.
This distinction matters. If a supplement raises a laboratory marker, researchers can reasonably ask whether that change leads to better health. The marker itself is not proof of a clinical benefit.
What Have NMN Trials Found?
Some small NMN trials have produced encouraging signals in narrowly defined groups.
In a 2021 randomized trial, 25 postmenopausal women with prediabetes and overweight or obesity received NMN or placebo for 10 weeks. NMN improved skeletal-muscle insulin sensitivity and related signaling. The study was important because it demonstrated a measurable metabolic effect in humans, but it was small, short, and limited to a specific population. It did not show that NMN prevents diabetes, reduces cardiovascular events, or extends life.
A 2022 randomized trial studied 250 milligrams of NMN daily in older men. NMN increased blood NAD+ and related metabolites. The investigators reported nominal improvements in gait speed and one grip-strength measure, while body composition did not change. Forty-two participants were randomized, but only 20 completed the 12-week assessment after protocol deviations. The authors appropriately called for larger validation studies.
A separate 14-day trial in 32 adults ages 55 to 80 found that a pharmaceutical-grade NMN formulation produced dose-related increases in blood NAD levels and was generally well tolerated. That study was designed mainly to assess pharmacology, not whether the product improved health or slowed aging.
These are useful scientific steps, but they do not establish that a retail NMN product produces noticeable energy, mobility, or longevity benefits.
What About Muscle, Energy, and Exercise?
Marketing commonly connects NAD+ to “cellular energy,” then implies that an NAD booster will increase a person’s energy or physical performance. The first statement describes biochemistry. The second requires a clinical trial.
A 2025 systematic review and meta-analysis evaluated randomized trials of NMN and NR involving adults whose average age was over 60. The authors concluded that current evidence did not support these supplements for preserving skeletal-muscle mass or function. Individual studies differed in product, dose, duration, population, and outcome measurement, which makes sweeping conclusions difficult.
People can also use the word “energy” in different ways. It may mean exercise capacity, daytime sleepiness, motivation, fatigue, mood, or cellular ATP production. A change in NAD metabolism does not automatically improve each of those experiences. Persistent fatigue deserves a clinical evaluation for common causes such as insufficient sleep, sleep apnea, anemia, thyroid disease, medication effects, mood disorders, infection, and cardiopulmonary disease.
Do NAD Boosters Extend Life or Prevent Dementia?
There is currently no human trial showing that NMN or NR extends lifespan. No adequately powered clinical trial has established that these supplements prevent dementia, heart attack, stroke, cancer, or disability in otherwise healthy adults.
Animal and laboratory studies help identify mechanisms and design trials, but cannot establish the same benefit in humans. Species, dose, environment, and study population all affect translation.
Terms such as “anti-aging” and “age reversal” can also hide the outcome being claimed. Is a product supposed to change a blood biomarker, improve walking speed, prevent disease, reduce frailty, or help someone live longer? Those are different claims requiring different evidence. A credible recommendation should identify the exact outcome and the quality of evidence supporting it.
What Is Known About Safety?
Short human studies have generally found oral NR and NMN to be tolerable at the tested doses. That provides some reassurance about short-term use under research conditions. It does not establish long-term safety, safety at every marketed dose, or safety for every patient.
Many trials lasted only weeks or months and enrolled relatively few participants. They cannot reliably detect uncommon effects or consequences emerging after years. Research-grade formulations also may not match products sold online.
People who are pregnant or breastfeeding, have active cancer or a cancer history, take multiple medications, or live with liver, kidney, cardiovascular, or metabolic disease should discuss these products with a qualified clinician. This caution does not mean NAD precursors are proven dangerous in those groups. It means the benefit-risk balance is uncertain and may depend on the individual clinical context.
How to Evaluate an NAD Product
Before spending money, ask a few practical questions:
- What exact ingredient and route were studied? Evidence for oral NR does not transfer automatically to NMN, NAD+ infusions, injections, sprays, or multi-ingredient blends.
- Did the study measure a meaningful outcome? A higher NAD-related blood level is different from better strength, cognition, function, or survival.
- Were people like me included? Results from a small trial in people with prediabetes may not apply to a healthy younger adult or someone with a complex illness.
- How long did the study last? A short tolerability trial cannot answer a long-term longevity question.
- Is product quality independently verified? Third-party testing can provide some assurance about identity and contaminants, but it does not prove that the product works.
- Does the marketing outrun the evidence? Be skeptical of guaranteed energy, disease prevention, detoxification, or reversal of aging.
The FDA updated its consumer information on August 27, 2026, and continues to emphasize that dietary supplements are not approved for safety and effectiveness before marketing. Manufacturers are responsible for their products, while much of the FDA’s oversight occurs after products reach the market.
The Bottom Line
NAD biology is scientifically important, and NR and NMN deserve continued study. Some formulations can raise NAD-related biomarkers, and selected small trials have found promising metabolic or functional signals. The evidence does not yet establish that these supplements slow human aging, extend life, prevent dementia, or reliably improve energy and physical function.
For most people, the foundations of healthy aging remain less glamorous and better supported: regular physical activity, adequate sleep, nutritious food, cardiovascular risk management, meaningful relationships, appropriate vaccinations, and timely medical care.
Brainology helps patients build individualized brain-health and longevity plans grounded in clinical evidence rather than marketing alone. A supplement discussion can be part of that plan, but it should begin with the goal, the evidence, the person’s health history, and what remains unknown.
This draft is for general education and does not provide individual medical advice. Do not start, stop, or replace prescribed treatment based on supplement marketing or this article.
References
- Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018;9:1286. Full text
- Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. PubMed | DOI
- Igarashi M, Miura M, Williams E, et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. NPJ Aging. 2022;8:5. PubMed | Full text
- Pencina KM, Lavu S, Dos Santos M, et al. MIB-626, an oral formulation of a microcrystalline unique polymorph of beta-nicotinamide mononucleotide, increases circulating nicotinamide adenine dinucleotide and its metabolome in middle-aged and older adults. Journal of Gerontology: Series A. 2023;78(1):90-96. PubMed | DOI
- Elhassan YS, Kluckova K, Fletcher RS, et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Reports. 2019;28(7):1717-1728.e6. PubMed
- Prokopidis K, Moriarty F, Bahat G, McLean J, Church DD, Patel HP. The effect of nicotinamide mononucleotide and riboside on skeletal muscle mass and function: a systematic review and meta-analysis. Journal of Cachexia, Sarcopenia and Muscle. 2025;16(3):e13799. PubMed | DOI
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements. Updated August 27, 2026. FDA